Henry Schein (HSIC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
12 May, 2026Voting matters and shareholder proposals
Board recommends voting FOR director nominees William K. Daniel and Max Lin, citing their independence and qualifications.
Board recommends voting AGAINST Proposal 4, a shareholder proposal to govern by majority vote, submitted by John Chevedden.
Shareholders are encouraged to review the full text of Proposal 4 and the company's opposition statement in the proxy statement.
Board of directors and corporate governance
William K. Daniel and Max Lin were added to the board as part of a strategic partnership with KKR, which invested $250 million and is the largest stockholder.
Both nominees meet all Nasdaq and SEC independence standards and serve on key committees.
Mr. Daniel contributed to CEO compensation design; Mr. Lin participated in the CEO search and evaluation process.
Executive compensation and say-on-pay
Mr. Daniel's experience includes overseeing executive compensation at Danaher Corporation, informing his role in designing compensation for the incoming CEO.
Latest events from Henry Schein
- Strong Q1 growth, margin expansion, and strategic focus position the company for 2026 targets.HSIC
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 delivered strong sales, margin, and EPS growth, with guidance and value initiatives reaffirmed.HSIC
Q1 20265 May 2026 - $13.2B FY2025 sales, digital transformation, and high-margin growth drive long-term value.HSIC
Corporate presentation5 May 2026 - Proxy details CEO transition, board reduction, pay-for-performance, and key governance votes.HSIC
Proxy filing8 Apr 2026 - Key votes include director elections, executive pay, auditor ratification, and majority voting.HSIC
Proxy filing8 Apr 2026 - $13.2B in 2025 sales with strong specialty, technology, and high-margin business growth.HSIC
Corporate presentation13 Mar 2026 - Dental segment growth, digital innovation, and leadership changes drive optimism for 2026.HSIC
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Operational shift, AI innovation, and specialty growth drive margin and market share gains.HSIC
Leerink Global Healthcare Conference 20269 Mar 2026 - Record sales and earnings growth in Q4 2025, with a strong outlook for 2026.HSIC
Q4 202524 Feb 2026